individuals.5 This variation is often most apparent between unrelated families, but intrafamilial heterogeneity may also be quite pronounced.6 Sporadic cases widen clinical heterogeneity even further.7-9 Despite this, the clinical features of unexplained ventricular hypertrophy and the histological findings of extensive myocyte disarray with interstitial fibrosis'0 were regarded as sufficiently specific to define a disease." 12 Other phenotypes with some features that overlap with those of "typical" hypertrophic cardiomyopathy have been more difficult to classify clinically. These include apical hypertrophic cardiomyopathy,"3 14 hypertrophic cardiomyopathy of the elderly,'5 and families with myocyte disarray and sudden death but without hypertrophy. '6 A more fundamental classification of these clinical entities is becoming possible with the insights provided by molecular genetics. Analyses in familial HCM show that genetic heterogeneity exceeds clinical heterogeneitythat is, hypertrophic cardiomyopathy is genetically not one disease but many. At least four separate disease genes can cause "classic" HCM, indicating greater complexity than might have been expected on clinical grounds. Whether such a genetic classification will be more useful than a clinical one will depend on the extent to which knowledge of the underlying molecular defect helps to predict clinical outcome. In addition knowledge of the underlying molecular defect will assist diagnosis and may provide important insights into the disease process and the potential for intervention.
Genetic analyses
Because familial hypertrophic cardiomyopathy is inherited as an autosomal dominant mendelian trait, all affected members of a given family must have an identical gene defect. The defect need not be the same in unrelated families with familial HCM, however; either a different mutation within the same gene or a mutation in another gene could be responsible. MISSENSE 
Four genes for sarcomeric proteins had been mapped to regions of chromosome 1 that include the CMH2 locus (fig 1) : genes encoding a skeletal actin, slow-twitch troponin I, the non-muscle isoform of a tropomyosin, and the human homologue of myosin binding protein-H. These candidate genes at the CMH2 locus have been investigated by the identification of intragenic STR markers to allow precise linkage mapping. Recombination between CMH2 and the genes encoding skeletal actin and non-muscle tropomyosin excluded these as HCM-causing genes at CMH2. In the initial screening of the fi cardiac MHC gene the entire coding sequence was screened but no mutations were identified in the coiled rod region.'9 Subsequent searches for mutations have largely ignored the rod region on the assumption that missense mutations in this region cannot produce the HCM phenotype. Some support for this strategy is provided by linkage data on families in which no mutations were found on screening, showing no evidence of missed mutations. 35 This implies that, if they occur at all, mutations in the rod causing disease are very infrequent. A single deletion mutation in the terminal portion of the rod has been reported," but without evidence of segregation with disease. Southern blot analyses in 20 probands with familial HCM did not find other examples of deletion mutations. 45 The feasibility of preclinical diagnosis has been shown in several kindreds. 19 22 26 The value of preclinical diagnosis will depend on the success of therapeutic interventions in modifying the disease process or its complications; this potential may be greatest in those individuals without established hypertrophy in whom HCM is diagnosed preclinically. Moreover, trials of treatments can now be performed in homogeneous groups of patients. Preliminary evaluation of interventions should be possible in transgenic mice that carry mutated myosin heavy chain genes; these models would allow testing of both conventional pharmacological treatments and possible genetic manipulations. Also important will be the degree to which the presence of a particular fi cardiac MHC mutation predicts the outcome for any individual, especially the risk of sudden death.
Does the presence of a fi cardiac MHC mutation in a child necessarily indicate that important disease will follow? While evaluation of the extent of correlation between phenotype and genotype is undertaken, the implications of preclinical screening programs within families with HCM will require careful evaluation.
PROGNOSTIC IMPLICATIONS OF SPECIFIC MYOSIN MUTATIONS
The finding of multiple different mutations within the JJ cardiac myosin gene raises the possibility that it is this allelic heterogeneity that determines the wide variation in severity of HCM in unrelated families. The influence of a specific mutation can be determined by studying individuals from unrelated familiessuch that differences in outcome are more likely to relate to the specific mutation that they have in common rather than other genetic or environmental influences. Different branches of single large pedigrees are also adequate for these analyses because in a dominant disease the only genetic material that all affected members will have in common will be the region of the genome carrying the mutation causing the disease.
Phenotype/genotype analyses have not shown clear differences between clinical variables such as the echocardiographic features of hypertrophy," but there were important differences in the survival of affected individuals. Kaplan-Meier analyses (fig 2) have identified some mutations associated S 7 group.bmj.com on April 13, 2017 -Published by http://heart.bmj.com/ Downloaded from with particularly poor prognosis (for example, Arg403Gln, Arg453Cys, and Arg7l9Trp), with a high incidence of sudden death and significantly shorter survival than is seen with other mutations.'922 30 Certain mutations seem to have an intermediate effect on survival (for example, Arg249Gln,'9) while three mutations have been reported to have a particularly good prognosis with near normal survival:
Val6O6Met,'9 Leu908Val,22 and Phe513Cys.30
These three mutations differ from others in that they do not involve a net change in charge and so would be predicted to cause less severe disturbance to the structure and function of the myosin polypeptide. It is notable that some of the affected members of three unrelated families with the conservative Val606Met mutation had pronounced ventricular hypertrophy but still tended to survive longer than individuals with other mutations.'9 These data suggest that the specific myosin mutation is a major determinant of survival and that knowledge of the precise defect may contribute significantly to the identification of those at increased risk of sudden death.
The findings with the three non-charge change mutations suggest that conservative substitutions may in general produce less severe disease. In addition, however, the location of the mutation within the globular head of the myosin polypeptide as well as the change in charge would be expected to determine the impact of each mutation. The tertiary structure of the head region of a myosin polypeptide has recently been established by x ray crystallography.47 This allows identification of the location of each ,B cardiac MHC mutation relative to the functional domains and prediction of changes in polypeptide folding and shape in response to particular amino acid substitutions. One striking finding is that the Arg403Gln mutation, which produces the most severe phenotype, is situated in a critical position relative to the cleft involved in actin binding.48 This finding was not predicted from the primary structure and so illustrates the potential value of this new data for determining the effects of the mutations causing HCM.
CLINICAL FEATURES OF INDIVIDUALS WITH MUTATIONS IN CARDIAC TROPONIN T AND TROPOMYOSIN
In a disease with three known disease genes, each of which is associated with multiple different mutations, the potential for phenotypic heterogeneity is considerable. For practical purposes it will be important to determine whether it is the disease locus itself or the specific mutation within it that most influences the natural history of hypertrophic cardiomyopathy in a given family.
With the ,B MHC gene locus the range of life expectancies for different mutations is as wide as is seen in the disease as a whole; no clinical features have been identified that distinguish the subgroup of families whose disease is accounted for by mutations in this gene. '9 46 Preliminary analyses of the other loci also suggest that specific mutations determine outcome and that classification by disease gene alone may not identify clinically distinct subsets. The families selected for the linkage analyses that ultimately identified the troponin T and a tropomyosin disease genes were chosen for their large size, rather than any phenotypic characteristics. Of the families now shown to have mutations in these genes, only one shows features that make it distinct from the typical range of HCM. One of the families shown to have an a tropomyosin missense mutation has significantly less myocardial hypertrophy than other familial HCM families, with many confirmed gene carriers with normal cross sectional echocardiograms.3842 In contrast, affected members of a family with a different a tropomyosin missense mutation have typical hypertrophy. Presumably, then this aspect of the phenotype relates to the particular mutation and is not a general characteristic of a tropomyosin mutations. INVOLVEMENT 
